Home » Stocks » AMPH

Amphastar Pharmaceuticals, Inc. (AMPH)

Stock Price: $20.18 USD 0.01 (0.02%)
Updated Jun 21, 2021 11:35 AM EDT - Market open
Market Cap 960.81M
Revenue (ttm) 368.18M
Net Income (ttm) 2.50M
Shares Out 47.52M
EPS (ttm) 0.05
PE Ratio 387.98
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $20.18
Previous Close $20.17
Change ($) 0.01
Change (%) 0.02%
Day's Open 20.17
Day's Range 20.04 - 20.26
Day's Volume 45,790
52-Week Range 16.91 - 22.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Commun...

5 days ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communi...

3 weeks ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuti...

1 month ago - GlobeNewsWire

Amphastar (AMPH) delivered earnings and revenue surprises of 42.11% and 6.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 58.82% over the past year to $0.27, whi...

1 month ago - Benzinga

Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021

1 month ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) --  Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviated...

1 month ago - GlobeNewsWire

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

RANCHO CUCAMONGA, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, ...

1 month ago - GlobeNewsWire

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

Other stocks mentioned: BHC, RDY, TEVA
2 months ago - Zacks Investment Research

RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, T...

2 months ago - GlobeNewsWire

Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.

Other stocks mentioned: BLUE, HGEN, QURE
2 months ago - Benzinga

RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company's Abbreviate...

2 months ago - GlobeNewsWire

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Other stocks mentioned: JAZZ, KNBWY, NSRGY, TSCDY
3 months ago - Zacks Investment Research

Amphastar (AMPH) delivered earnings and revenue surprises of 14.29% and 7.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 128.57% year over year to $0.16, whic...

3 months ago - Benzinga

Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020

3 months ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December ...

3 months ago - GlobeNewsWire

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

RANCHO CUCAMONGA, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, To...

3 months ago - GlobeNewsWire

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AQUA, BBDC, BHVN, CFX, CRHM, GBT, HASI ...
4 months ago - Seeking Alpha

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New ...

5 months ago - GlobeNewsWire

Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: AMRX, BIIB, HZNP, PAHC, SUPN
6 months ago - Investopedia

Growth-focused investors may want to consider the following small-cap stocks as they represent companies whose trailing 12-month pro forma earnings per share improved significantly on a year-over-year b...

Other stocks mentioned: GLDD, PBH
7 months ago - GuruFocus

Amphastar Pharmaceuticals, Inc. (AMPH) Management on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Amphastar Pharmaceuticals' (AMPH) Management on Q3 2020 Results - Quick Version Earnings Call Transcript

7 months ago - Seeking Alpha

Amphastar (AMPH) delivered earnings and revenue surprises of 15.39% and -8.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020

7 months ago - GlobeNewsWire

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

7 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Amphastar.

8 months ago - Zacks Investment Research

Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.

8 months ago - Zacks Investment Research

RANCHO CUCAMONGA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated...

8 months ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communicati...

9 months ago - GlobeNewsWire

Amphastar Pharmaceuticals' (AMPH) Management on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

On Thursday, August 06, Amphastar Pharmaceuticals (NASDAQ: AMPH) will release its latest earnings report.

10 months ago - Benzinga

RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30,...

10 months ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communicatio...

1 year ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communicatio...

1 year ago - GlobeNewsWire

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q3 2020.

Other stocks mentioned: CRON, NLTX
1 year ago - Investopedia

RANCHO CUCAMONGA, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Amphastar® Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has appro...

1 year ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO and Dan Dischner, Vice President of Corporate Communica...

1 year ago - GlobeNewsWire

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 year ago - Zacks Investment Research

RANCHO CUCAMONGA, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”),  today announces that the U.S. Food and Drug Administration (“FDA”) has gran...

1 year ago - GlobeNewsWire

RANCHO CUCAMONGA, Calif., April 13, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”), a California-based, specialty, generic pharmaceutical compan...

1 year ago - GlobeNewsWire

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Amphastar (AMPH) delivered earnings and revenue surprises of 40.00% and 3.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About AMPH

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone fo... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 25, 2014
CEO
Jack Zhang
Employees
1,980
Stock Exchange
NASDAQ
Ticker Symbol
AMPH
Full Company Profile

Financial Performance

In 2020, AMPH's revenue was $349.85 million, an increase of 8.53% compared to the previous year's $322.36 million. Earnings were $1.40 million, a decrease of -97.13%.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is 21.60, which is an increase of 7.06% from the latest price.

Price Target
$21.60
(7.06% upside)
Analyst Consensus: Buy